The Antidote: Inside the World of New Pharma (66 page)

(
pp. 49
–53) Interviews with Josh Boger, Rich Aldrich, and Michael Partridge. Gabi Horn, “Vertex Vortex,”
POZ
, September 1998; Alana Kumbier,
PopPolitics.com
, “Despite Ad Images, HIV Still Not Carefree,”
AlterNet
, posted June 12, 2001; Tom Abate, “Passing the ‘BioBucks’—Small Investors Aren’t In on the Joke/Inflated Deal Values Sometimes Only Way Firms Can Raise Funds,”
SFGate.com
, June 14, 1999.

(
pp. 53
–60) Interviews with Mark Murcko, Josh Boger, Ken Boger, Rich Aldrich, and Vicki Sato. Andrew Pollack, “Finding Gold in Scientific Pay Dirt,”
New York Times
, June 28, 2000; Philip Ball, “Bursting the Genomic Bubble,”
Nature
, published online March 31, 2010; Siddhartha Mukherjee,
The Emperor of All Maladies
, Scribner, 2010; Daniel Vasella,
Magic Cancer Bullet
, HarperCollins, 2003.

(
pp. 61
–64) Interviews with Josh Boger, Ann Kwong, Roger Tung, Dave Deininger, Vicki Sato, and John Thomson.

(
pp. 64
–67) Interviews with Josh Boger, Vicki Sato, and Mark Murcko. Amy Tsao, “The Vertex Vortex: Drug Development at Hyperspeed?”
BusinessWeek
, March 15, 2001; Andrew Pollack, “Vertex Buys Biotechnology Rival for $592 Million,”
New York Times
, May 1, 2001; Kevin Fogarty, “Speed Is the Vertex Creed,”
BioIT World
, April 7, 2002.

(
pp. 67
–70) Interviews with Josh Boger, Vicki Sato, Bob Beall, and Rich Aldrich. Vertex’s decision to partner with the nonprofit Cystic Fibrosis Foundation is the subject of an excellent academic case study, which I relied on heavily in reporting this section: Robert F. Higgins, Sophie Lamontagne, and Brent Kazan, “Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech,”
Harvard Business School
, October 2007; revised July 2010.

(
pp. 70
–73) Interviews with John Alam, Josh Boger, and Vicki Sato.

(
pp. 73
–76) Interviews with Josh Boger, Ken Boger, Vicki Sato, and Mark Murcko. United States District Court, District of Massachusetts, In Re VERTEX PHARMACEUTICALS, INC. SECURITIES LITIGATION, Master File No. O3 11852 PBS.

(
pp. 76
–78) Interviews with Josh Boger and Vicki Sato. Andrew Pollack, “Announcement on a Hepatitis C Drug Is Expected Today,”
New York Times
, January 7, 2002; Tom Abate, “H&Q Conference Has Matured Along with the Biotech Industry,”
SFGate.com
, January 7, 2002.

(
pp. 78
–81) Interviews with John Thomson, Paul Negulescu, Mark Murcko, Roger Tung, and Eric Olson.

(
pp. 81
–83) Interviews with Vicki Sato, Ann Kwong, Josh Boger, Roger Tung, and John Thomson. Ryan McBride, “How Eli Lilly Let a Billion-Dollar Molecule Slip Away, and Make a Fortune for Vertex,” Xconomy, August 4, 2010.

(
pp. 84
–88) Interviews with Josh Boger, Ian Smith, Ken Boger, and Vicki Sato.

(
pp. 88
–90) Interviews with Ian Smith, John Thomson, Jon Moore, Vicki Sato, and Chris Lepre. Andrew Pollack, “Despite Billions for Discoveries, Pipeline of Drugs Is Far from Full,”
New York Times
, April 19 2002; Andrew Pollack, “Awaiting the Genome Payoff,”
New York Times
, June 14, 2010; Allison Connolly, “Bio-Layoffs Cool Once Booming Job Market,”
Boston Business Journal
, June 30, 2003.

(
pp. 90
–94) Interviews with Josh Boger, Vicki Sato, and Peter Mueller. Again, deeply reported academic case studies were invaluable here for piecing together critical developments during a formative period: Gary Pisano, Lee Fleming, and Eli Peter Strick, “Vertex Pharmaceuticals: R&D Portfolio Management (A),”
Harvard Business School
, June 20, 2006; Francesca Gino and Gary Pisano, “Vertex Pharmaceuticals: R&D Portfolio Management (B)&(C),”
HBS
, April 25, 2006.